Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

228.89USD
24 May 2016
Change (% chg)

-- (--)
Prev Close
$228.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,444,422
52-wk High
$340.34
52-wk Low
$195.50

AGN

Chart for AGN

About

Allergan plc, formerly Actavis plc, is a pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products (brand, branded or specialty brand), medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. It operates through... (more)

Overall

Beta: 0.65
Market Cap(Mil.): $90,539.02
Shares Outstanding(Mil.): 395.56
Dividend: --
Yield (%): --

Financials

  AGN Industry Sector
P/E (TTM): -- 34.43 35.43
EPS (TTM): -5.63 -- --
ROI: -1.68 13.73 13.09
ROE: -3.52 14.71 14.22

BRIEF-Allergan announces FDA acceptance of NDA filing for oxymetazoline hci cream 1.0%

* Allergan announces FDA acceptance of NDA filing for oxymetazoline hci cream 1.0%

May 24 2016

BRIEF-Allergan's botox wins Japanese approval to treat crow's feet lines

* Allergan's botox vista (botulinum toxin type a) receives national marketing authorisation in japan for treatment of crow's feet lines in adult patients

May 23 2016

Allergan CEO says company is 'weeks away' from closing Teva deal

Allergan Plc Chief Executive Brent Saunders said on Monday the company expects to close the $40.5 billion sale of its generic medicines portfolio to Teva Pharmaceutical Industries Ltd in a matter of weeks, opening the door for new acquisitions.

May 23 2016

Allergan CEO says company is 'weeks away' from closing Teva deal

NEW YORK Allergan Plc Chief Executive Brent Saunders said on Monday the company expects to close the $40.5 billion sale of its generic medicines portfolio to Teva Pharmaceutical Industries Ltd in a matter of weeks, opening the door for new acquisitions.

May 23 2016

UPDATE 1-Allergan CEO says company is "weeks away" from closing Teva deal

NEW YORK, May 23 Allergan Plc Chief Executive Brent Saunders said on Monday the company expects to close the $40.5 billion sale of its generic medicines portfolio to Teva Pharmaceutical Industries Ltd in a matter of weeks, opening the door for new acquisitions.

May 23 2016

BRIEF-Allergan CEO says company is "weeks away" from closing Teva deal

* Allergan CEO says company is free to do multibillion dollar deals after Teva transaction closes

May 23 2016

Investors made bets on Allergan just weeks before deal collapsed

BOSTON Hedge funds, including Baupost Group, Davidson Kempner Capital Management and Magnetar Financial, made investments in Allergan Plc during the first quarter, betting that the company would become the world's biggest drug maker.

May 17 2016

Investors made bets on Allergan just weeks before deal collapsed

BOSTON, May 16 Hedge funds, including Baupost Group, Davidson Kempner Capital Management and Magnetar Financial, made investments in Allergan Plc during the first quarter, betting that the company would become the world's biggest drug maker.

May 16 2016

HIGHLIGHTS-Top U.S. hedge funds bet on Netflix, Yahoo, consumer stocks

NEW YORK, May 16 Former SAC executive Gabe Plotkin's Melvin Capital took a new position in streaming video service Netflix Inc, buying 950,000 shares and a call option for 1.45 million shares, according to regulatory filings on Monday. Hoplite Capital also took a new position in Netflix, buying 236,456 shares, while Blue Ridge took a new position, buying 1.4 million shares.

May 16 2016

BRIEF-Allergan announces positive pivotal trial results for Oculeve Intranasal Tear Neurostimulator

* Allergan announces positive pivotal trial results for oculeve intranasal tear neurostimulator

May 16 2016

Earnings vs. Estimates